-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 29, Shanghai AG Baifa announced that its subsidiary Ark Biopharmaceutical Limited and Commave Therapeutics, SA (Commave) under Gurnet Point Capital (GPC) have signed an exclusive license agreement to trade an innovative drug AZSTARYS® for the treatment of ADHD
.
According to the terms of the agreement, AGCO Baifa paid Commave including advance payment and milestone payments for development and sales, with a total amount of US$105.
5 million
.
In addition, it also includes an annual commission based on AZSTARYS's annual sales in Greater China
.
And AGCO Baifa will get the exclusive development, production and commercialization rights of AZSTARYS in Greater China
.
On December 24, Tasly Pharmaceutical Group Co.
, Ltd.
also issued an announcement stating that it has obtained the exclusive license from SutroBiopharma, Inc.
of the United States to develop and commercialize a target exclusively in China (ie, Mainland China, Hong Kong and Macau Special Administrative Regions, and Taiwan).
Conjugate the drug STRO-002 to the folate receptor α (FRα) antibody
.
Tasly will pay Sutro US$40 million in advance and potentially up to US$345 million in development and commercialization milestone payments, as well as an agreed percentage of sales commissions
.
It is reported that STRO-002 is the third-generation antibody-conjugated drug (ADC) developed by Sutro and has global intellectual property rights
.
At present, no ADC product targeting FRα has been approved for marketing in the world.
There are 3 ADC products in the clinical stage.
Among them, STRO-002 is a product that does not distinguish the expression level of FRα in patients in clinical trials
.
The analysis believes that, in fact, it is already normal in the industry that domestic pharmaceutical companies improve their innovative drug R&D pipelines by introducing foreign new drugs.
.
Due to the characteristics of high R&D investment, high risk, and long payback period for new drug research and development; and in recent years, the country has been vigorously promoting pharmaceutical innovation and other reasons; in order to enhance innovation strength, more and more domestic pharmaceutical companies are currently adopting "authorized introduction" "Model to introduce innovative projects to further enhance the enriched product line and improve competitiveness in innovation
.
According to statistics, as of September this year, there have been more than 90 domestic innovative drug license in projects, of which more than 30 transactions exceeded 100 million U.
S.
dollars, and 14 exceeded 300 million U.
S.
dollars
.
In October, at least eight Chinese biopharmaceutical companies have reached agreement on new drug introduction cooperation, including Shanghai Pharmaceuticals, Luoxin Pharmaceuticals, East China Pharmaceuticals, Yehui Pharmaceuticals, China Resources Double Crane, and Hansen Pharmaceuticals
.
Among them, Shanghai Pharmaceuticals and Hansen Pharmaceuticals both reached two cooperations within one month
.
It is worth mentioning that, in the context of domestic pharmaceutical companies accelerating the introduction of new drugs and continuously enriching the pipeline of innovative drugs, the innovation achievements of pharmaceutical companies have gradually begun to appear
.
Take Huadong Medicine as an example, earlier it introduced a FRα ADC IMGN853 (Mirvetuximab Soravtansine)
.
On December 1, Huadong Medicine and its partner ImmunoGen jointly announced that the key US single-arm clinical trial (SORAYA trial) of IMGN853 has reached the primary research end point.
It is expected to submit a biological product license application (BLA )
.
From an overall point of view, the industry believes that under the background of increasing support for pharmaceutical innovation at the policy level, the popularity of the innovative drug capital market will continue to rise
.
At the same time, a large number of listed pharmaceutical companies will continue to introduce new drugs to accelerate innovation
.
.
According to the terms of the agreement, AGCO Baifa paid Commave including advance payment and milestone payments for development and sales, with a total amount of US$105.
5 million
.
In addition, it also includes an annual commission based on AZSTARYS's annual sales in Greater China
.
And AGCO Baifa will get the exclusive development, production and commercialization rights of AZSTARYS in Greater China
.
On December 24, Tasly Pharmaceutical Group Co.
, Ltd.
also issued an announcement stating that it has obtained the exclusive license from SutroBiopharma, Inc.
of the United States to develop and commercialize a target exclusively in China (ie, Mainland China, Hong Kong and Macau Special Administrative Regions, and Taiwan).
Conjugate the drug STRO-002 to the folate receptor α (FRα) antibody
.
Tasly will pay Sutro US$40 million in advance and potentially up to US$345 million in development and commercialization milestone payments, as well as an agreed percentage of sales commissions
.
It is reported that STRO-002 is the third-generation antibody-conjugated drug (ADC) developed by Sutro and has global intellectual property rights
.
At present, no ADC product targeting FRα has been approved for marketing in the world.
There are 3 ADC products in the clinical stage.
Among them, STRO-002 is a product that does not distinguish the expression level of FRα in patients in clinical trials
.
The analysis believes that, in fact, it is already normal in the industry that domestic pharmaceutical companies improve their innovative drug R&D pipelines by introducing foreign new drugs.
.
Due to the characteristics of high R&D investment, high risk, and long payback period for new drug research and development; and in recent years, the country has been vigorously promoting pharmaceutical innovation and other reasons; in order to enhance innovation strength, more and more domestic pharmaceutical companies are currently adopting "authorized introduction" "Model to introduce innovative projects to further enhance the enriched product line and improve competitiveness in innovation
.
According to statistics, as of September this year, there have been more than 90 domestic innovative drug license in projects, of which more than 30 transactions exceeded 100 million U.
S.
dollars, and 14 exceeded 300 million U.
S.
dollars
.
In October, at least eight Chinese biopharmaceutical companies have reached agreement on new drug introduction cooperation, including Shanghai Pharmaceuticals, Luoxin Pharmaceuticals, East China Pharmaceuticals, Yehui Pharmaceuticals, China Resources Double Crane, and Hansen Pharmaceuticals
.
Among them, Shanghai Pharmaceuticals and Hansen Pharmaceuticals both reached two cooperations within one month
.
It is worth mentioning that, in the context of domestic pharmaceutical companies accelerating the introduction of new drugs and continuously enriching the pipeline of innovative drugs, the innovation achievements of pharmaceutical companies have gradually begun to appear
.
Take Huadong Medicine as an example, earlier it introduced a FRα ADC IMGN853 (Mirvetuximab Soravtansine)
.
On December 1, Huadong Medicine and its partner ImmunoGen jointly announced that the key US single-arm clinical trial (SORAYA trial) of IMGN853 has reached the primary research end point.
It is expected to submit a biological product license application (BLA )
.
From an overall point of view, the industry believes that under the background of increasing support for pharmaceutical innovation at the policy level, the popularity of the innovative drug capital market will continue to rise
.
At the same time, a large number of listed pharmaceutical companies will continue to introduce new drugs to accelerate innovation
.
